XML 72 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss attributable to Myriad Genetics, Inc. stockholders $ (263.3) $ (112.0) $ (27.2)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization 61.9 52.7 62.8
Non-cash lease expense 11.3 11.7 12.8
Loss on termination of lease 7.7 0.0 0.0
Stock-based compensation expense 40.7 38.1 36.3
Deferred income taxes (4.0) (30.8) (32.1)
Unrecognized tax benefits 3.4 (1.1) (2.6)
Net realized losses on marketable investment securities 1.5 0.0 0.0
Loss on inventory 0.0 0.0 6.5
Impairment of goodwill and long-lived assets 0.0 16.9 1.8
Gain on sale of businesses and assets 0.0 0.0 (162.0)
Other non-cash adjustments 2.9 1.7 1.5
Changes in assets and liabilities:      
Prepaid expenses and other current assets 0.2 1.6 (6.6)
Trade accounts receivable (12.5) (10.3) (8.8)
Inventory (1.8) (2.9) 1.6
Prepaid taxes 0.7 0.7 89.9
Other assets 0.6 (0.9) (3.6)
Tenant improvement allowance received 16.3 18.0 0.0
Accounts payable (3.7) (3.5) 9.2
Accrued liabilities 27.4 (81.2) 65.7
Deferred revenue (0.2) (5.0) (26.6)
Net cash provided by (used in) operating activities (110.9) (106.3) 18.6
CASH FLOWS FROM INVESTING ACTIVITIES:      
Capital expenditures (63.2) (45.3) (18.0)
Capitalization of internal-use software costs (10.1) 0.0 0.0
Acquisitions, net of cash acquired 0.0 (57.2) 0.0
Proceeds from sale of business and assets 0.0 0.0 379.1
Purchases of marketable investment securities 0.0 (103.2) (147.8)
Proceeds from maturities and sales of marketable investment securities 105.2 128.2 61.1
Net cash provided by (used in) investing activities 31.9 (77.5) 274.4
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from common stock issued under stock-based compensation plans 6.0 6.3 91.8
Payment of tax withheld for common stock issued under stock-based compensation plans (8.8) (10.6) (11.5)
Proceeds from underwritten public offering, net of costs and discounts 117.6 0.0 0.0
Proceeds from revolving credit facility 80.0 0.0 0.0
Fees associated with issuance and refinancing of revolving credit facility (1.7) (0.7) (1.2)
Repayment of revolving credit facility (40.0) 0.0 (226.4)
Payment of contingent consideration recognized at acquisition 0.0 (3.0) (3.3)
Payment on finance leases (0.2) 0.0 0.0
Net cash provided by (used in) financing activities 152.9 (8.0) (150.6)
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash 0.6 (0.6) (0.6)
Net increase (decrease) in cash, cash equivalents, and restricted cash 74.5 (192.4) 141.8
Cash, cash equivalents, and restricted cash at beginning of the period 66.4 258.8 117.0
Cash, cash equivalents, and restricted cash at end of the period $ 140.9 $ 66.4 $ 258.8